• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Dansey Roger D converted options into 2,167 shares, increasing direct ownership by 32% to 8,916 units (SEC Form 4)

    5/21/25 4:57:32 PM ET
    $INO
    Medical/Dental Instruments
    Health Care
    Get the next $INO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DANSEY ROGER D

    (Last) (First) (Middle)
    660 W. GERMANTOWN PIKE SUITE 110

    (Street)
    PLYMOUTH MEETING PA 19462

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INOVIO PHARMACEUTICALS, INC. [ INO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/21/2025 M 2,167 A (1) 8,916 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 05/21/2025 M 2,167 (1) (1) Common Stock 2,167 $0 0 D
    Explanation of Responses:
    1. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025.
    Remarks:
    /s/ Roger Dansey 05/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INO

    DatePrice TargetRatingAnalyst
    7/9/2025$5.00Overweight
    Piper Sandler
    5/14/2024$20.00Overweight
    Stephens
    1/25/2024$4.00Perform → Outperform
    Oppenheimer
    11/9/2022Buy → Hold
    Maxim Group
    11/1/2022$2.00Neutral → Underperform
    BofA Securities
    7/19/2022$5.00 → $4.00Sector Perform
    RBC Capital Mkts
    5/11/2022Outperform → Perform
    Oppenheimer
    3/2/2022$6.00 → $5.00Sector Perform
    RBC Capital
    More analyst ratings

    $INO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Sumner Michael John converted options into 2,916 shares, increasing direct ownership by 20% to 17,850 units (SEC Form 4)

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    7/1/25 4:08:06 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shea Jacqueline Elizabeth

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    5/21/25 4:58:59 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Humeau Laurent

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    5/21/25 4:58:48 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc

    8/14/25 12:22:00 PM ET
    $FATE
    $INO
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year endCompleted design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration (FDA)Continuing to advance commercial preparations for potential launch of INO-3107 in 2026 if approved by FDAPLYMOUTH MEETING, Pa., Aug. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second qu

    8/12/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

    Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2 Partial data into the third 12-month period (Year 3 - median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeriesPLYMOUTH MEETING, Pa., Aug. 11, 2025 /PRNewswire/ -- INOVIO (NASD

    8/11/25 8:05:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    SEC Filings

    View All

    Inovio Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    8/12/25 4:08:16 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Inovio Pharmaceuticals Inc.

    10-Q - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    8/12/25 4:01:08 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Inovio Pharmaceuticals Inc.

    8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    7/7/25 7:30:42 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Inovio Pharma with a new price target

    Piper Sandler initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $5.00

    7/9/25 8:30:13 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on Inovio Pharma with a new price target

    Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

    5/14/24 8:01:14 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Inovio Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

    1/25/24 7:27:17 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Leadership Updates

    Live Leadership Updates

    View All

    Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

    LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy. Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and indust

    7/1/25 7:00:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

    PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

    1/9/25 8:04:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

    Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

    7/2/24 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Financials

    Live finance-specific insights

    View All

    INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

    PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at ht

    8/4/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

    On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgeryAnnounced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encod

    5/13/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

    PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

    4/29/25 8:05:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

    SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    4/26/24 4:01:17 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    1/22/24 10:20:28 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    7/10/23 2:07:33 PM ET
    $INO
    Medical/Dental Instruments
    Health Care